• Free Consultation
  • Free IP Audit
  • International Brand Protection
  • About
  • Careers
  • Global IP Blogs
  • Contact
  • Login
Lexprotector.com
+1 – 888 890 6411 [email protected]
  • Trademark
    • Trademark Search
      • Indian Trademark Search
      • USA Trademark Search
      • EU Trademark Search
      • UK Trademark Search
      • Canada Trademark Search
      • Australia Trademark Search
      • New Zealand Trademark Search
    • Trademark Registration
      • Indian Trademark Registration
      • USA Trademark Registration
      • EU Trademark Registration
      • UK Trademark Registration
      • Canada Trademark Registration
      • Australia Trademark Registration
      • New Zealand Trademark Registration
    • Trademark Monitoring
      • Indian Trademark Monitoring
      • USA Trademark Monitoring
      • EU Trademark Monitoring
      • UK Trademark Monitoring
      • Canada Trademark Monitoring
      • Australia Trademark Monitoring
      • New Zealand Trademark Monitoring
    • Trademark Consultation
      • Indian Trademark Consultation
      • USA Trademark Consultation
      • EU Trademark Consultation
      • UK Trademark Consultation
      • Canada Trademark Consultation
      • Australia Trademark Consultation
      • New Zealand Trademark Consultation
  • Patent
    • Patent Search
      • Prior Art Search
      • Freedom to Operate Search
      • Utility Patent Search
    • Patent Drafting
      • USA Provisional Patent Drafting
      • USA Non-Provisional Patent Drafting
      • Indian Provisional Patent Drafting
      • Indian Complete Specification Drafting
    • Patent Filing
      • USA Provisional Patent Filing
      • USA Non-Provisional Patent Filing
      • Indian Provisional Patent Filing
      • Indian Complete Specification Filing
    • Patent Consultation
      • Patent Consultation
      • Utility Patent Consultation
      • Design Patent Consultation
    • Design Patent
      • Design Patent Search
      • EU Design Patent Filing
      • USA Design Patent Filing
      • India Industrial Design Filing
  • IP Enforcement
    • Violation Search
    • DMCA Takedown Notice
    • IP Enforcement
      • Copyright Enforcement
      • Trademark Enforcement
      • Utility Patent Enforcement
      • Design Patent Enforcement
    • Amazon Brand Registration
    • Copyright Registration
      • Indian Copyright Registration
      • USA Copyright Registration
  • IP Management
    • IP Due Diligence
    • IP Auditing
    • IP Valuation
    • IP Licensing
    • IP Consultation
+1 – 888 890 6411 [email protected]

‘Nexavar’ Attains Judicial Nirvana

  • Older
  • Newer

‘Nexavar’ Attains Judicial Nirvana

The Curious Case of Sorafenib tosylate, as I had put it earlier, has finally reached its climax. In an order passed on 12 December 2014, the Supreme Court of India has declined to interfere with the order passed by IPAB upholding the grant of Compulsory License to Natco Pharma for the drug ‘Nexavar’. Supreme Court’s order has finally put a full stop to the first chapter of Compulsory Licensing related to a Patent in India. This means that Natco Pharma can freely market the generic version of the drug till year 2020, when the Patent will expire.2

The compulsory license was granted on the ground that only a small population had access to the drug at an exorbitant price of around Rs.2,80,000. The order was earlier challenged by Bayer in the Bombay High Court that refused to interfere with the original decision of IPAB.

The order is significant not only because it has been decided by keeping the interest of general public at its helm who was deprived of such an essential drug, but also for concluding a prolonged judicial battle whose disposal was curiously awaited. However, the court in its order has kept all questions of Law open for now, which means this order alone cannot be used as a precedent till a detailed judgment is not released. As far as branded drug makers are concerned, this is a double whammy after what happened to Novartis a few years back. Only time can tell how much impact this finished chapter will cause in the Pharmaceutical Sector. Meanwhile, it seems cancer patients in India can extend their Diwali celebrations till the upcoming New Year.

')}

Quick ‘Nexavar’ Attains Judicial Nirvana